Table 2.
The observed and expressed values of the combined treatment effects
| Effect | Creatinine (mg/dl) |
Effect | ALT (U/L) |
Effect | Tumor volume (mm3) |
Combined treatment | |||
|---|---|---|---|---|---|---|---|---|---|
| 0.4 ± 0.3a,b | OV | 39.2 ± 5.6a,b | OV | 535.3 ± 97.9a,b | OV | EC/CuNPs/R | |||
| Ad | 0.43 ± 0.05 | EV | Ad | 38.98 ± 6.1 | EV | An | 924.4 ± 106.0 | EV | |
| Effect |
GSH (mg/g tissue) |
Effect |
MDA (nM/g tissue) |
Effect |
Calcium (mg/g tissue) |
||||
| 1.31 ± 0.08a,b | OV | 91.1 ± 2.2a,b | OV | 124.3 ± 12.2a,b | OV | EC/CuNPs/R | |||
| Ad | 1.3 ± 0.45 | EV | Sy | 75.2 ± 7.43 | EV | Sy | 46.9 ± 2.6 | EV | |
| Effect |
NF-κB (expression fold) |
Effect |
Casp-3 (pg/100 mg tissue) |
Effect |
CAT (µM/g tissue) |
||||
| 0.3 ± 0.03a,b | OV | 5.77 ± 0.22a,b | OV | 11.8 ± 0.26a,b | OV | EC/CuNPs/R | |||
| An | 0.48 ± 0.5 | EV | An | 25.59 ± 0.96 | EV | Ad | 12.2 ± 0.44 | EV | |
|
P38MAPK (expression fold) |
Cyclin D1 (expression fold) |
||||||||
| 0.3 ± 0.22a,b | OV | 0.4 ± 0.03 | OV | EC/CuNPs/R | |||||
| An | 0.4 ± 0.03 | EV | An | 0.63 ± 0.05 | EV | ||||
Data are expressed as mean ± SD. OV, observed value; EV, expected value; Sy, synergistic effect; Ad, additive effect; An, antagonistic effect. Where a, significance compared to control and b, significance compared to EC